Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes – Published online 22/07/2025

Yuko Yamaguchi, Hitoshi Kuwata, Masahiro Imura, Shota Moyama, Ryota Usui, Mari Matsushiro, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino & Yuji Yamazaki

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown remarkable glycaemic and weight-lowering effects, yet its precise mechanisms remain incompletely understood. In this issue, Yamaguchi and Kuwata et al (https://doi.org/10.1007/s00125-025-06493-5) provide clinical evidence from a prospective study that tirzepatide can improve insulin sensitivity within a short treatment period, as assessed by hyperinsulinaemic–euglycaemic clamp in Japanese individuals with obesity and type 2 diabetes. Such early enhancement of insulin sensitivity supports preclinical hypotheses that tirzepatide exerts metabolic benefits beyond weight loss, possibly via weight-independent GIP receptor-mediated pathways. The authors highlight that these findings bridge basic and clinical research, reinforcing the concept that incretin-based therapy may directly modulate insulin action. As new incretin-related agents emerge, understanding these early pharmacodynamic effects will be essential for clarifying their place in the broader metabolic disease landscape. The authors conclude that this study offers a critical piece of translational evidence in the evolving field of incretin pharmacology.

All News